NextConsensus // Decision-window intelligence

Know when new evidence makes a reassessment unavoidable.

Evidence hardens before institutions act. We identify the evidence patterns that determine the Ratification Gap — so you can reassess your strategy before the window closes.

For strategy, HEOR, and commercial leads: know when new evidence has reached a stable hardening pattern—and whether your current position has become dangerous to maintain.

One Claim To Reassess
One Decision Safety / Regulatory
Window Status Open / Closing

01 // THE PROBLEM

New evidence arrives before you reassess.

Evidence hardens before institutions formally update. By identifying specific hardening patterns, we identify when new evidence has become too stable to ignore—and when the window to reassess is narrowing.

[AUDIT_STATUS: MEASURED] · We identify hardening patterns, what holds, and whether the window to reassess is still open.

When this matters:

  • Safety signal emergence
  • Regulatory label updates
  • Guideline language shifts
  • Medical affairs field readiness
  • Post-marketing surveillance reviews

02 // THE OUTPUT

A reassessment brief your team can forward to leadership.

Each brief answers: Can this claim still be challenged, and how much time do we have?

Window status (Open / Narrowing / Closing), what holds, what is under stress, what would reverse the read, and a suggested action envelope for your reassessment strategy.

Reassessment Brief Structure For Safety / Regulatory / Medical Affairs
  • Window Status: Open / Narrowing / Closing
  • What Holds: Stable evidence that remains defensible
  • What Is Under Stress: New evidence that threatens the claim
  • What Would Reverse: Evidence that would restore defensibility
  • Suggested Action Envelope: Reassessment actions before the window closes
Trust Boundary

We measure the Ratification Gap. We do not predict safety outcomes or guarantee regulatory clearance.

Start

Have a claim whose defensibility just changed?

Send the claim, the decision date, and what new evidence arrived. We respond within one business day with fit, limits, and whether the window to reassess is still open.

Requests require a verified institutional email address and are subject to current lane authorization limits.

Today's Read finerenone-cardiorenal
Hardening
Signal 0.38 / Gate 0.65
Phase 1b pending review. Other lanes: dossier-build.

Visual Debug

Page:

Width: px

Theme: